Brief: Editas Medicine And Azzur Group Expand Partnership To Accelerate Editas' Manufacturing Capabilities For Advancing The Edit-301 Program Through Approval To Commercialization
27/07/2023 15:10
Editas Medicine Inc EDIT.O :
* EDITAS MEDICINE AND AZZUR GROUP EXPAND PARTNERSHIP TO
ACCELERATE
EDITAS' MANUFACTURING CAPABILITIES FOR ADVANCING THE EDIT-301
PROGRAM THROUGH APPROVAL TO COMMERCIALIZATION
Source text for Eikon: ID:nPn9Lqzk6a
Further company coverage: EDIT.O
Recent news on Editas Medicine
See all newsEditas Medicine, Inc. reports results for the quarter ended June 30 - Earnings Summary
Editas Medicine, Inc. expected to post a loss of 27 cents a share - Earnings Preview
Editas Medicine Q2 net loss narrows and beats estimates
Brief: Editas Medicine Q2 Net Income USD -18.23 Million Vs. IBES Estimate USD -27 Million
Editas Medicine down after $125 mln stock-and-warrants offering